Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Adjuvant continuous metronomic adriamycin + cyclophosphamide followed by weekly nab-paclitaxel for high-risk early-stage breast cancer.

Cho E, Wu Q, Rubinstein L, Linden H, Gralow J, Specht J, Gadi V, Ellis G.

Breast J. 2018 Jul;24(4):610-614. doi: 10.1111/tbj.13013. Epub 2018 Mar 13.

PMID:
29532546
2.

NCCN Guidelines Insights: Antiemesis, Version 2.2017.

Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M.

J Natl Compr Canc Netw. 2017 Jul;15(7):883-893. doi: 10.6004/jnccn.2017.0117.

PMID:
28687576
3.

Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New.

Cho E, Schwemm AK, Rubinstein LM, Stevenson PA, Gooley TA, Ellis GK, Specht JM, Livingston RB, Linden HM, Gadi VK.

Clin Breast Cancer. 2015 Oct;15(5):e277-85. doi: 10.1016/j.clbc.2015.04.002. Epub 2015 Apr 24.

4.

Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.

Lipton A, Smith MR, Ellis GK, Goessl C.

Clin Med Insights Oncol. 2012;6:287-303. doi: 10.4137/CMO.S8511. Epub 2012 Aug 16.

5.

Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA.

Clin Cancer Res. 2011 Jul 15;17(14):4799-805. doi: 10.1158/1078-0432.CCR-10-3321. Epub 2011 Jul 12.

6.

PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.

Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi VK, Kurland BF, Schubert EK, Muzi M, Mankoff DA.

Clin Cancer Res. 2011 Apr 15;17(8):2400-9. doi: 10.1158/1078-0432.CCR-10-2649. Epub 2011 Mar 1.

7.

Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012.

Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB.

J Clin Oncol. 2011 Mar 10;29(8):1014-21. doi: 10.1200/JCO.2009.27.6543. Epub 2011 Jan 10.

8.

The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.

Lipton A, Uzzo R, Amato RJ, Ellis GK, Hakimian B, Roodman GD, Smith MR.

J Natl Compr Canc Netw. 2009 Oct;7 Suppl 7:S1-29; quiz S30.

9.

Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).

Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston RB, Martino S, Perez EA, Hortobagyi GN, Sher D, Stock W.

Breast Cancer Res Treat. 2010 Jan;119(2):391-8. doi: 10.1007/s10549-009-0597-5.

10.

Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.

Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, Kim D.

Breast Cancer Res Treat. 2009 Nov;118(1):81-7. doi: 10.1007/s10549-009-0352-y. Epub 2009 Mar 24.

PMID:
19308727
11.

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S.

J Clin Oncol. 2008 Oct 20;26(30):4875-82. doi: 10.1200/JCO.2008.16.3832. Epub 2008 Aug 25.

PMID:
18725648
12.

Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA.

J Clin Oncol. 2008 Sep 20;26(27):4449-57. doi: 10.1200/JCO.2007.15.4385. Epub 2008 Jul 14.

13.

Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).

Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunnwald LK, Mankoff DA.

Breast Cancer Res Treat. 2007 Sep;105(1):87-94. Epub 2007 Feb 1.

PMID:
17268819
14.

Antiemesis.

Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, McNulty R, Nabati L, Todaro B, Urba S, Yowell S; National comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2007 Jan;5(1):12-33. No abstract available.

PMID:
17239323
15.

Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.

Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA.

J Clin Oncol. 2006 Jun 20;24(18):2793-9. Epub 2006 May 8.

PMID:
16682724
16.

Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.

Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Lawton TJ, Barlow WE, Schubert EK, Mankoff DA.

Cancer. 2005 Feb 15;103(4):680-8.

17.

Antiemesis clinical practice guidelines in oncology.

Ettinger DS, Bierman PJ, Bradbury B, Ellis G, Ignoffo RJ, Kirkegaard S, Kloth D, Krauss A, Kris MG, Lim D, Markiewicz MA, McNulty R, Noonan K, Stucky-Marshall L, Todaro B, Urba S, Yowell S; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2004 Sep;2(5):470-90. No abstract available.

PMID:
19780255
18.

Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC).

Bellon JR, Livingston RB, Eubank WB, Gralow JR, Ellis GK, Dunnwald LK, Mankoff DA.

Am J Clin Oncol. 2004 Aug;27(4):407-10.

PMID:
15289736
19.

Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer.

Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, Lindsley S, Austin-Seymour M, Livingston R.

AJR Am J Roentgenol. 2004 Aug;183(2):479-86.

PMID:
15269044
20.

HER-2 testing in breast cancer using parallel tissue-based methods.

Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM.

JAMA. 2004 Apr 28;291(16):1972-7.

PMID:
15113815
21.

Potential of chemotherapy-herb interactions in adult cancer patients.

McCune JS, Hatfield AJ, Blackburn AA, Leith PO, Livingston RB, Ellis GK.

Support Care Cancer. 2004 Jun;12(6):454-62. Epub 2004 Feb 27.

PMID:
14991387
22.

Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, Lawton TJ, Linden HM, Livingston RB.

J Nucl Med. 2003 Nov;44(11):1806-14.

23.

Amphiphysin paraneoplastic syndrome: a delayed diagnosis of breast carcinoma.

Georgian-Smith D, Ellis GK, Kraft GH.

Breast J. 2003 Jul-Aug;9(4):316-8.

PMID:
12846868
24.

Myalgias and arthralgias associated with paclitaxel.

Garrison JA, McCune JS, Livingston RB, Linden HM, Gralow JR, Ellis GK, West HL.

Oncology (Williston Park). 2003 Feb;17(2):271-7; discussion 281-2, 286-8. Review.

25.

[Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow.

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Charlop AW, Tseng J, Rinn KJ, Livingston RB.

Nucl Med Biol. 2002 Oct;29(7):719-27.

PMID:
12381452
26.

Dose-dense anthracycline-based chemotherapy for node-positive breast cancer.

Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T.

J Clin Oncol. 2002 Sep 1;20(17):3637-43.

PMID:
12202664
27.

Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, Tseng J, Livingston RB.

J Nucl Med. 2002 Apr;43(4):500-9.

Supplemental Content

Loading ...
Support Center